Hang in there!!, page-26

Since things are pretty much fixed in stone now, I wanted to mention this.

Regeneron was recently refused FDA approval for the 8mg Afibrecept dosing regimen because of manufacturing concerns even though the Photon trial was successful. If you look at the details however, the phase 2 Opthea trial results of the combination therapy resulted in significantly better visual acuity than the improvement documented in the Photon trial....
and the Opthea trials were noteworthy for the exception performance of the control arms, some of the best ever seen. We could speculate as to why and although its difficult to compare results from one trial to another, it's defnitely food for thought Mr Mutton.

I think I will be participating.